
    
      Follicular lymphoma patients with a large tumor burden will be randomized for 18 months of
      treatment with either:

        -  Arm A: CHVP + alpha2a-interferon. Patients will receive 12 courses of CHVP
           (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and
           prednisolone 40 mg/m² for 5 days), one course every month for 6 months then one course
           every other month for 12 additional months associated with alpha2a-interferon 4.5
           millions units sub-cutaneously three times a week for 18 months.

        -  Arm B: CHVP + alpha2a-interferon + rituximab. Patients will receive 6 monthly courses of
           CHVP (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and
           prednisolone 40 mg/m² for 5 days) associated with 6 infusions of rituximab (375 mg/m2)
           associated with alpha2a-interferon 4.5 millions units sub-cutaneously three times a week
           for 18 months.
    
  